AR076770A1 - Inmunoglobulinas humanas anti-cd52 - Google Patents

Inmunoglobulinas humanas anti-cd52

Info

Publication number
AR076770A1
AR076770A1 ARP100101677A ARP100101677A AR076770A1 AR 076770 A1 AR076770 A1 AR 076770A1 AR P100101677 A ARP100101677 A AR P100101677A AR P100101677 A ARP100101677 A AR P100101677A AR 076770 A1 AR076770 A1 AR 076770A1
Authority
AR
Argentina
Prior art keywords
humanized
refers
humanized immunoglobulin
chain
heavy
Prior art date
Application number
ARP100101677A
Other languages
English (en)
Spanish (es)
Inventor
Bruce L Roberts
William M Siders
Srinivas Shankara
William Harold Brondyk
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43085579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076770(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR076770A1 publication Critical patent/AR076770A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
ARP100101677A 2009-05-13 2010-05-13 Inmunoglobulinas humanas anti-cd52 AR076770A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17783709P 2009-05-13 2009-05-13

Publications (1)

Publication Number Publication Date
AR076770A1 true AR076770A1 (es) 2011-07-06

Family

ID=43085579

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101677A AR076770A1 (es) 2009-05-13 2010-05-13 Inmunoglobulinas humanas anti-cd52

Country Status (19)

Country Link
US (5) US8617554B2 (enExample)
EP (3) EP3683317A3 (enExample)
JP (4) JP5894912B2 (enExample)
KR (5) KR20170113704A (enExample)
CN (3) CN102459628A (enExample)
AR (1) AR076770A1 (enExample)
AU (1) AU2010249003B2 (enExample)
BR (1) BRPI1013085A2 (enExample)
CA (2) CA2761800C (enExample)
HK (2) HK1222682A1 (enExample)
IL (2) IL216141B (enExample)
MX (1) MX2011012047A (enExample)
MY (1) MY160126A (enExample)
NZ (2) NZ621170A (enExample)
RU (2) RU2603743C2 (enExample)
SG (2) SG10201608169QA (enExample)
TW (3) TW201825115A (enExample)
WO (1) WO2010132659A2 (enExample)
ZA (1) ZA201108077B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131712A2 (en) 2008-04-25 2009-10-29 Duke University Medical Center Regulatory b cells and their uses
RU2603743C2 (ru) 2009-05-13 2016-11-27 Джензим Корпорейшн Иммуноглобулины k cd52 человека
US9617343B2 (en) 2009-05-13 2017-04-11 Genzyme Corporation Methods and compositions for treating lupus
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
US20140193420A1 (en) 2011-04-18 2014-07-10 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-itm2a antibody
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
WO2013185165A1 (en) * 2012-06-14 2013-12-19 The Walter And Eliza Hall Institute Of Medical Research Cd-52 antibodies and their use in determining and enhancing an immune response in a subject
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
US20150299315A1 (en) * 2012-10-22 2015-10-22 Becton, Dickinson And Company Non-b-lineage cells capable of producing antibody
US10365275B2 (en) 2013-03-12 2019-07-30 Institute of Arthritis Reasearch, LLC Immunologically active polypeptide
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
KR102042174B1 (ko) 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR102060540B1 (ko) * 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
KR102186363B1 (ko) * 2013-09-06 2020-12-04 삼성전자주식회사 c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물
KR102192591B1 (ko) * 2013-09-09 2020-12-18 삼성전자주식회사 c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
JP2018521979A (ja) 2015-06-03 2018-08-09 ボストン バイオメディカル， インコーポレイテッド 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
KR102506091B1 (ko) 2016-05-02 2023-03-07 프로테나 바이오사이언시즈 리미티드 타우 면역요법
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
CN109415434B (zh) 2016-05-02 2022-12-30 普罗塞纳生物科学有限公司 识别tau的抗体
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018112407A1 (en) 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
CN110546167A (zh) * 2017-04-21 2019-12-06 建新公司 以抗-cd52抗体治疗多发性硬化症
WO2018204546A2 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
US11396538B2 (en) 2017-12-20 2022-07-26 Radimmune Therapeutics, Inc. Antibodies to centrin-1, methods of making, and uses thereof
CN113544148B (zh) * 2018-12-19 2024-04-05 胡默波斯生物医学公司 中和乙型肝炎病毒的抗体和其用途
FI4285929T3 (fi) 2018-12-20 2025-12-30 Humabs Biomed Sa Hbv:n yhdistelmähoito
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
CN109929835A (zh) * 2019-03-27 2019-06-25 中国人民解放军第四军医大学 一种鼠单克隆抗体功能轻链可变区基因的扩增方法
CN120775051A (zh) 2019-05-21 2025-10-14 诺华股份有限公司 Cd19结合分子及其用途
JP7678768B2 (ja) * 2019-07-02 2025-05-16 テリックス ファーマシューティカルズ （イノベーションズ） ピーティーワイ リミテッド 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体
WO2021223719A1 (zh) * 2020-05-08 2021-11-11 亘喜生物科技（上海）有限公司 一种抗cd19抗体的抗体及其制备和应用
AU2021381372A1 (en) * 2020-11-19 2023-07-06 Genzyme Corporation Flow cytometry attenuated reporter expression (flare) multiple reporter system and methods of use thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2025031965A1 (en) * 2023-08-04 2025-02-13 Cimeio Therapeutics Ag Discernible cell surface protein variants of cd52 for use in cell therapy

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH0684377B2 (ja) 1986-04-17 1994-10-26 協和醗酵工業株式会社 新規化合物ｄｃ―８８ａ及びｄｃ―８９ａ１
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU618989B2 (en) * 1988-02-12 1992-01-16 British Technology Group Limited Improvements in or relating to antibodies
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9108056D0 (en) * 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
ATE271557T1 (de) 1994-04-22 2004-08-15 Kyowa Hakko Kogyo Kk Dc-89 derivat
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
JP2003514903A (ja) 1999-11-24 2003-04-22 イムノージェン インコーポレーテッド タキサンを含有する細胞傷害薬とその治療への利用
MXPA02008472A (es) 2000-03-03 2004-03-26 Cambridge Antibody Tech Anticuerpos humanos contra la eotaxina y su uso.
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) * 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
WO2004042032A2 (en) 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) * 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
JPWO2004087210A1 (ja) * 2003-03-31 2006-06-29 麒麟麦酒株式会社 抗ｃｄ５２抗体による調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物
WO2005017149A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
JP4804357B2 (ja) 2003-11-01 2011-11-02 メルク パテント ゲーエムベーハー 改変抗ｃｄ５２抗体
US20060204496A1 (en) * 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
KR101247908B1 (ko) * 2004-09-02 2013-03-26 제넨테크, 인크. 항-ｆｃ-감마 ｒｉｉｂ 수용체 항체 및 그의 용도
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
MX2007014672A (es) * 2005-05-24 2008-04-08 Avestha Gengraine Tech Pvt Ltd Metodo recombinante para la produccion de un anticuerpo monoclonal hacia cd52 para el tratamiento de leucemia linfocitica cronica.
NZ564092A (en) 2005-05-27 2010-05-28 Biogen Idec Inc TWEAK binding antibodies
EP1966244B1 (en) * 2005-12-30 2012-03-21 Merck Patent GmbH Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
EP2012814B1 (en) * 2006-04-12 2013-05-22 Genzyme Corporation Methods of treating autoimmune diseases
DK2066352T3 (en) 2006-09-13 2016-02-29 Alcafleu Man Gmbh & Co Kg TREATMENT OF MULTIPLE SCLEROSIS (MS) WITH CAMPATH-1H
NZ597915A (en) 2007-02-28 2013-08-30 Merck Sharp & Dohme Combination therapy for treatment of immune disorders
JP2010530857A (ja) * 2007-06-22 2010-09-16 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 神経系障害、特に感染性海綿状脳症及びアルツハイマー病を治療するためのｃｄ５２抗原に対する抗体の使用
RU2603743C2 (ru) 2009-05-13 2016-11-27 Джензим Корпорейшн Иммуноглобулины k cd52 человека
EP2429584A4 (en) 2009-05-13 2013-02-20 Genzyme Corp TREATMENT PROCEDURE AND COMPOSITIONS
US9617343B2 (en) 2009-05-13 2017-04-11 Genzyme Corporation Methods and compositions for treating lupus
KR101832201B1 (ko) 2009-07-15 2018-02-28 에임 쎄라퓨틱스 비.브이. 그람-양성 박테리아 특이적 결합 화합물
CA3086837C (en) 2010-07-16 2023-03-07 Adimab, Llc Libraries comprising segmental pools, and methods for their preparation and use
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
CN108025083B (zh) 2014-10-09 2021-09-03 建新公司 糖工程化的抗体药物缀合物
CN110546167A (zh) 2017-04-21 2019-12-06 建新公司 以抗-cd52抗体治疗多发性硬化症

Also Published As

Publication number Publication date
US11945874B2 (en) 2024-04-02
TW201825115A (zh) 2018-07-16
EP2429582A4 (en) 2013-01-23
HK1205152A1 (en) 2015-12-11
IL262639A (en) 2018-12-31
MY160126A (en) 2017-02-28
NZ596384A (en) 2014-03-28
KR20160005143A (ko) 2016-01-13
KR20170113704A (ko) 2017-10-12
AU2010249003A1 (en) 2011-11-03
JP5894912B2 (ja) 2016-03-30
EP2429582A2 (en) 2012-03-21
JP2014195474A (ja) 2014-10-16
HK1222682A1 (en) 2017-07-07
EP3683317A3 (en) 2020-09-30
WO2010132659A2 (en) 2010-11-18
RU2603743C2 (ru) 2016-11-27
CA2939492C (en) 2019-03-19
JP2016093194A (ja) 2016-05-26
KR20160103160A (ko) 2016-08-31
NZ621170A (en) 2015-08-28
CN110016081A (zh) 2019-07-16
CN104231084B (zh) 2019-04-23
EP2998405B1 (en) 2019-12-11
US20140341910A1 (en) 2014-11-20
IL216141B (en) 2018-11-29
ZA201108077B (en) 2013-01-30
US20200040091A1 (en) 2020-02-06
BRPI1013085A2 (pt) 2020-11-03
TWI529247B (zh) 2016-04-11
SG10201608169QA (en) 2016-11-29
CN104231084A (zh) 2014-12-24
RU2011150516A (ru) 2013-06-20
CA2939492A1 (en) 2010-11-18
TW201636367A (zh) 2016-10-16
JP2012526558A (ja) 2012-11-01
AU2010249003B2 (en) 2015-08-20
JP2018029624A (ja) 2018-03-01
US20220010024A1 (en) 2022-01-13
RU2016142225A (ru) 2018-12-18
EP2998405A1 (en) 2016-03-23
EP3683317A2 (en) 2020-07-22
CA2761800A1 (en) 2010-11-18
CN102459628A (zh) 2012-05-16
KR101537840B1 (ko) 2015-07-22
CA2761800C (en) 2016-09-27
IL216141A0 (en) 2012-01-31
KR20120111932A (ko) 2012-10-11
US20160208010A1 (en) 2016-07-21
WO2010132659A3 (en) 2011-01-06
KR20140102764A (ko) 2014-08-22
SG176060A1 (en) 2011-12-29
MX2011012047A (es) 2011-12-14
TWI614267B (zh) 2018-02-11
US20120100152A1 (en) 2012-04-26
US8617554B2 (en) 2013-12-31
TW201043694A (en) 2010-12-16

Similar Documents

Publication Publication Date Title
AR076770A1 (es) Inmunoglobulinas humanas anti-cd52
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
CR20140029A (es) Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada
MX2012009168A (es) Raton de cadena ligera comun.
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
BRPI0606547A2 (pt) anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado
MX382398B (es) Proteinas de union a antigeno st2.
CL2008003784A1 (es) Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo
AR084141A1 (es) Anticuerpos neutralizadores anti-ccl20
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
MX348071B (es) Variantes de fc.
AR084210A1 (es) PROTEINAS DE UNION AL TNF-a
EA201270207A1 (ru) Анти-muc1 антитела
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
MX2015011957A (es) Anticuerpos biespecificos anti-tnf-anti-il-17.
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
MX2015012540A (es) Ratón de cadena ligera común.
JOP20200161A1 (ar) أجسام مضادة أحادية النسيلة وطرق استخدامها
MX2014010449A (es) Anticuerpos a metaloproteinasa de matriz 9.
MX388698B (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
TR201900638T4 (tr) Anti̇-cd52 anti̇korlari.
CY1120326T1 (el) Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι για τη χρηση και την ταυτοποιηση τους
EA201992312A1 (ru) Биспецифические анти-cd37-антитела, моноклональные анти-cd37-антитела и способы их применения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure